| Titolo | Fase | Stato | Sede patologia | Strutture coinvolte | Dettaglio |
Studio prospettico osservazione sull’angiosarcoma localizzato di ogni sede |
NA |
in corso |
Angiosarcoma |
- SC Oncologia Clinica Sperimentale dei Sarcomi e Tumori Rari |
|
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS A CDK4/6 INHIBITOR AND LETROZOLE VERSUS PLACEBO PLUS A CDK4/6 INHIBITOR AND LETROZOLE IN PATIENTS WITH ENDOCRINE-SENSITIVE PIK3CA-MUTATED, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER |
III |
in corso |
CARCINOMA MAMMARIO |
- SC Oncologia Clinica Sperimentale di Senologia |
|
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF TAR-210 ERDAFITINIB INTRAVESICAL DELIVERY SYSTEM VERSUS INVESTIGATOR’S CHOICE OF INTRAVESICAL CHEMOTHERAPY IN PARTICIPANTS WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER WITH SUSCEPTIBLE FGFR ALTERATIONS WHO HAD RECEIVED INTRAVESICAL BACILLUS CALMETTE-GUÉRIN (BCG) |
III |
in corso |
CANCRO ALLA VESCICA |
- SC Oncologia Clinica Sperimentale Uro - Ginecologica |
|
Uno studio randomizzato di fase II su Cemiplimab più TEDOPì come terapia di mantenimento nel NSCLC positivo per ctDNA. |
II |
in corso |
NSCLC |
- SC Oncologia Clinica Sperimentale Toraco - Polmonare |
|
A PHASE I/II RANDOMIZED MULTI-COHORT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF GSK5733584 IN COMBINATION WITH ANTI-CANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS |
I/II |
in corso |
TUMORI SOLIDI |
- SC Sperimentazioni Cliniche |
